We are live on ! Find out more

Sight Sciences

SGHT

Market cap $513M

9.32 USD

-0.25

2.61%

At close Updated Oct 30, 4:00 PM EDT

1 day

-2.61%

5 days

3.9%

1 month

-0.43%

3 months

77.19%

6 months

127.87%

Year to date

24.6%

1 year

83.46%

5 years

-65.02%

10 years

-72.18%

About: Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Employees: 186

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 60%

Negative 6.7%

Zacks Investment Research

Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?

Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

MENLO PARK, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the third quarter ended September 30, 2026, after the market close on Wednesday, November 4, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

Why Is Sight Sciences Stock Gaining Thursday?

Sight Sciences, Inc. (NASDAQ:SGHT) stock gained Thursday after H.C. Wainwright initiated coverage with a Buy rating and a $14 price forecast.

Why Is Sight Sciences Stock Gaining Thursday?

Sight Sciences: Signs Of Progress, But Plenty Of Work Remains

Sight Sciences is a cautious 'buy,' as recent reimbursement wins and product momentum support a positive outlook, offset by liquidity pressures and ongoing reimbursement and utilization challenges. SGHT's OMNI Ultra Surgical System launch and updated TearCare label provide incremental adoption tailwinds, but procedure costs/reimbursement and surgeon preference remain key hurdles. Q2 revenue grew 20% with strong dry eye business acceleration, improved gross margins, and reduced cash burn; Aetna coverage adds 25 million insured lives to the glaucoma business.

Sight Sciences: Signs Of Progress, But Plenty Of Work Remains

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives, today announced the commercial availability of the OMNI® Ultra Surgical System (OMNI Ultra), an expansion of its pioneering ab interno canaloplasty platform. The new technology will be featured at this year's American Academy of Ophthalmology (AAO) annual meeting held on October 9-12 in New Orleans, Louisiana.

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the TearCare® System (TearCare) Indications for Use to state:

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.

Sight Sciences Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™